Entera Bio Ltd. (NASDAQ:ENTX - Get Free Report) was the recipient of a significant growth in short interest in the month of February. As of February 15th, there was short interest totalling 104,500 shares, a growth of 59.5% from the January 31st total of 65,500 shares. Based on an average daily volume of 114,000 shares, the days-to-cover ratio is presently 0.9 days.
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of the stock. Parkman Healthcare Partners LLC raised its position in Entera Bio by 2.4% during the third quarter. Parkman Healthcare Partners LLC now owns 411,076 shares of the company's stock valued at $781,000 after acquiring an additional 9,558 shares in the last quarter. Signature Estate & Investment Advisors LLC purchased a new stake in shares of Entera Bio in the third quarter valued at approximately $90,000. Perigon Wealth Management LLC purchased a new stake in shares of Entera Bio in the fourth quarter valued at approximately $325,000. Northern Trust Corp purchased a new stake in shares of Entera Bio in the fourth quarter valued at approximately $450,000. Finally, Knoll Capital Management LLC increased its position in shares of Entera Bio by 51.5% in the fourth quarter. Knoll Capital Management LLC now owns 5,881,879 shares of the company's stock valued at $12,470,000 after buying an additional 2,000,000 shares in the last quarter. 14.11% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
Separately, HC Wainwright reaffirmed a "buy" rating and set a $10.00 target price on shares of Entera Bio in a report on Monday, November 11th.
View Our Latest Report on ENTX
Entera Bio Stock Up 2.6 %
Shares of Entera Bio stock traded up $0.05 on Tuesday, reaching $1.98. 50,274 shares of the stock were exchanged, compared to its average volume of 151,719. The business has a 50 day moving average price of $2.30 and a two-hundred day moving average price of $2.00. The firm has a market capitalization of $70.85 million, a price-to-earnings ratio of -7.62 and a beta of 1.62. Entera Bio has a twelve month low of $1.30 and a twelve month high of $3.35.
Entera Bio Company Profile
(
Get Free Report)
Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.
Further Reading
Before you consider Entera Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Entera Bio wasn't on the list.
While Entera Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
